{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:54:33Z","timestamp":1768683273375,"version":"3.49.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"merck kgaa","doi-asserted-by":"publisher","award":["CrossRef Funder ID: 10.13039\/100009945"],"award-info":[{"award-number":["CrossRef Funder ID: 10.13039\/100009945"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40262-021-01089-9","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T15:02:36Z","timestamp":1639234956000},"page":"167-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-5943","authenticated-orcid":false,"given":"Robert","family":"Hermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Krajcsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Fluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Seithel-Keuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afrim","family":"Bytyqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Munafo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"1089_CR1","unstructured":"The Multiple Sclerosis International Federation. Atlas of MS. 3rd ed. 2020."},{"issue":"Suppl. 1","key":"1089_CR2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl. 1):S5-48.","journal-title":"Mult Scler Relat Disord."},{"key":"1089_CR3","unstructured":"Mavenclad 10 mg tablets. Summary of product characteristics (SmPC). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf. Accessed 8 Jun 2021."},{"issue":"9648","key":"1089_CR4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"issue":"5","key":"1089_CR5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg S\u00f8rensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"key":"1089_CR6","unstructured":"Mavenclad prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022561s000lbl.pdf. Accessed 8 Jul 2021."},{"key":"1089_CR7","doi-asserted-by":"crossref","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e360.","DOI":"10.1212\/NXI.0000000000000360"},{"key":"1089_CR8","doi-asserted-by":"crossref","first-page":"175628641985498","DOI":"10.1177\/1756286419854986","volume":"12","author":"O Stuve","year":"2019","unstructured":"Stuve O, Soelberg Soerensen P, Leist T, Giovannoni G, Hyvert Y, Damian D, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:1756286419854986.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"1089_CR9","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","volume":"265","author":"B Ceronie","year":"2018","unstructured":"Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol. 2018;265(5):1199\u2013209.","journal-title":"J Neurol"},{"key":"1089_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-021-09994-3","author":"F Carlini","year":"2021","unstructured":"Carlini F, Ivaldi F, Gualandi F, Boschert U, Centonze D, Matarese G, et al. Different susceptibility of T and B cells to cladribine depends on their levels of deoxycytidine kinase activity linked to activation status. J Neuroimmune Pharmacol. 2021. https:\/\/doi.org\/10.1007\/s11481-021-09994-3.","journal-title":"J Neuroimmune Pharmacol"},{"key":"1089_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01065-3","author":"R Hermann","year":"2021","unstructured":"Hermann R, Krajcsi P, Fluck M, Seithel-Keuth A, Bytyqi A, Galazka A, et al. Review of transporter substrate, inhibitor and inducer characteristics of cladribine. Clin Pharmacokinet. 2021. https:\/\/doi.org\/10.1007\/s40262-021-01065-3.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1089_CR12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14656566.2013.754012","volume":"14","author":"G Comi","year":"2013","unstructured":"Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother. 2013;14(1):123\u201336.","journal-title":"Expert Opin Pharmacother"},{"key":"1089_CR13","first-page":"5","volume":"15","author":"C Salvat","year":"2009","unstructured":"Salvat C, Curchod M-L, Guedj E, Peixoto H, Guerrier M, Wojcik J, et al. Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis. Mult Scler. 2009;15:5\u2013150.","journal-title":"Mult Scler."},{"key":"1089_CR14","doi-asserted-by":"crossref","unstructured":"Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G. P1141: innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg\/kg in CLARITY and CLARITY Extension. Presented at: 4th Congress of the European Academy of Neurology; 16\u201319 June 2018;23(s3):598.","DOI":"10.26226\/morressier.59a3edabd462b8028d895161"},{"key":"1089_CR15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, Rieckmann P, S\u00f8rensen PS, Vermersch P, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374.","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"1089_CR16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-018-0695-9","volume":"58","author":"R Hermann","year":"2019","unstructured":"Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A. The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet. 2019;58(3):283\u201397.","journal-title":"Clin Pharmacokinet"},{"key":"1089_CR17","doi-asserted-by":"crossref","unstructured":"Young JD, Yao SY, Baldwin JM, Cass CE, Baldwin SA. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med. 2013;34(2\u20133):529\u201347.","DOI":"10.1016\/j.mam.2012.05.007"},{"issue":"1","key":"1089_CR18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","volume":"36","author":"RC Boswell-Casteel","year":"2017","unstructured":"Boswell-Casteel RC, Hays FA. Equilibrative nucleoside transporters: a review. Nucleos Nucleot Nucl. 2017;36(1):7\u201330.","journal-title":"Nucleos Nucleot Nucl."},{"issue":"5","key":"1089_CR19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/cpt.1516","volume":"106","author":"KWK Cheung","year":"2019","unstructured":"Cheung KWK, van Groen BD, Spaans E, van Borselen MD, de Bruijn A, Simons-Oosterhuis Y, et al. A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics, and localization. Clin Pharmacol Ther. 2019;106(5):1083\u201392.","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"1089_CR20","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.3390\/ijms20215303","volume":"20","author":"S Oswald","year":"2019","unstructured":"Oswald S, M\u00fcller J, Neugebauer U, Schr\u00f6ter R, Herrmann E, Pavenst\u00e4dt H, et al. Protein abundance of clinically relevant drug transporters in the human kidneys. Int J Mol Sci. 2019;20(21):5303.","journal-title":"Int J Mol Sci"},{"issue":"317","key":"1089_CR21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.taap.2016.12.021","volume":"15","author":"L Rosenbrier Ribeiro","year":"2017","unstructured":"Rosenbrier Ribeiro L, Ian SR. A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm. Toxicol Appl Pharmacol. 2017;15(317):41\u201350.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1089_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphar.2015.00013","volume":"6","author":"M Pastor-Anglada","year":"2015","unstructured":"Pastor-Anglada M, P\u00e9rez-Torras S. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol. 2015;6:13.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1089_CR23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/cells9040956","volume":"9","author":"KA Jacobson","year":"2020","unstructured":"Jacobson KA, Reitman ML. Adenosine-related mechanisms in non-adenosine receptor drugs. Cells. 2020;9(4):956.","journal-title":"Cells"},{"key":"1089_CR24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fphar.2018.00606","volume":"9","author":"M Pastor-Anglada","year":"2018","unstructured":"Pastor-Anglada M, P\u00e9rez-Torras S. Emerging roles of nucleoside transporters. Front Pharmacol. 2018;9:606.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1089_CR25","doi-asserted-by":"crossref","first-page":"F200","DOI":"10.1152\/ajprenal.00007.2007","volume":"293","author":"VL Damaraju","year":"2007","unstructured":"Damaraju VL, Elwi AN, Hunter C, Carpenter P, Santos C, Barron GM, et al. Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney. Am J Physiol Renal Physiol. 2007;293(1):F200\u201311.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1089_CR26","doi-asserted-by":"crossref","unstructured":"Vlachodimou A, Konstantinopoulou K, AP IJ, Heitman LH. Affinity, binding kinetics and functional characterization of draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1). Biochem Pharmacol. 2020;172:113747.","DOI":"10.1016\/j.bcp.2019.113747"},{"issue":"1\u20133","key":"1089_CR27","first-page":"75","volume":"568","author":"RW Li","year":"2007","unstructured":"Li RW, Tse CM, Man RY, Vanhoutte PM, Leung GP. Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists. Eur J Pharmacol. 2007;568(1\u20133):75\u201382.","journal-title":"Eur J Pharmacol"},{"issue":"36","key":"1089_CR28","doi-asserted-by":"crossref","first-page":"26675","DOI":"10.1074\/jbc.M513421200","volume":"281","author":"RP Owen","year":"2006","unstructured":"Owen RP, Badagnani I, Giacomini KM. Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. J Biol Chem. 2006;281(36):26675\u201382.","journal-title":"J Biol Chem"},{"issue":"4","key":"1089_CR29","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1074\/jbc.M007746200","volume":"276","author":"MW Ritzel","year":"2001","unstructured":"Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem. 2001;276(4):2914\u201327.","journal-title":"J Biol Chem"},{"issue":"3","key":"1089_CR30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.tpj.6500303","volume":"5","author":"I Badagnani","year":"2005","unstructured":"Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005;5(3):157\u201365.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"1089_CR31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/mol.105.015768","volume":"69","author":"KM King","year":"2006","unstructured":"King KM, Damaraju VL, Vickers MF, Yao SY, Lang T, Tackaberry TE, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol. 2006;69(1):346\u201353.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"1089_CR32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.leu.2403271","volume":"18","author":"M Pastor-Anglada","year":"2004","unstructured":"Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia. 2004;18(3):385\u201393.","journal-title":"Leukemia"},{"issue":"1\u20133","key":"1089_CR33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejphar.2012.06.015","volume":"690","author":"M Hiratochi","year":"2012","unstructured":"Hiratochi M, Tatani K, Shimizu K, Kuramochi Y, Kikuchi N, Kamada N, et al. Hypouricemic effects of novel concentrative nucleoside transporter 2 inhibitors through suppressing intestinal absorption of purine nucleosides. Eur J Pharmacol. 2012;690(1\u20133):183\u201391.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1089_CR34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/0091270009335002","volume":"49","author":"L Li","year":"2009","unstructured":"Li L, Koo SH, Limenta LMG, Han L, Lee EJD, Hashim KB, et al. Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. J Clin Pharmacol. 2009;49(6):661\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1089_CR35","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Assessing the effects of food on drugs in INDs and NDAs: clinical pharmacology considerations. 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations."},{"issue":"2","key":"1089_CR36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/1352458504ms992oa","volume":"10","author":"S Quesnel","year":"2004","unstructured":"Quesnel S, Feinstein A. Multiple sclerosis and alcohol: a study of problem drinking. Mult Scler. 2004;10(2):197\u2013201.","journal-title":"Mult Scler"},{"issue":"5","key":"1089_CR37","first-page":"1021","volume":"44","author":"SW Krauss","year":"1993","unstructured":"Krauss SW, Ghirnikar RB, Diamond I, Gordon AS. Inhibition of adenosine uptake by ethanol is specific for one class of nucleoside transporters. Mol Pharmacol. 1993;44(5):1021\u20136.","journal-title":"Mol Pharmacol"},{"issue":"5 Pt 1","key":"1089_CR38","doi-asserted-by":"crossref","first-page":"C1175","DOI":"10.1152\/ajpcell.1992.262.5.C1175","volume":"262","author":"LE Nagy","year":"1992","unstructured":"Nagy LE. Ethanol metabolism and inhibition of nucleoside uptake lead to increased extracellular adenosine in hepatocytes. Am J Physiol. 1992;262(5 Pt 1):C1175\u201380.","journal-title":"Am J Physiol"},{"key":"1089_CR39","doi-asserted-by":"crossref","unstructured":"Acevedo CG, Huambachano A, Perez E, Rojas S, Bravo I, Contreras E. Effect of ethanol on human placental transport and metabolism of adenosine. Placenta. 1997;18(5\u20136):387\u201392.","DOI":"10.1016\/S0143-4004(97)80038-0"},{"issue":"5","key":"1089_CR40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1530-0277.2009.00897.x","volume":"33","author":"DS Allen-Gipson","year":"2009","unstructured":"Allen-Gipson DS, Jarrell JC, Bailey KL, Robinson JE, Kharbanda KK, Sisson JH, et al. Ethanol blocks adenosine uptake via inhibiting the nucleoside transport system in bronchial epithelial cells. Alcohol Clin Exp Res. 2009;33(5):791\u20138.","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"1089_CR41","first-page":"365","volume":"276","author":"IR Coe","year":"1996","unstructured":"Coe IR, Dohrman DP, Constantinescu A, Diamond I, Gordon AS. Activation of cyclic AMP-dependent protein kinase reverses tolerance of a nucleoside transporter to ethanol. J Pharmacol Exp Ther. 1996;276(2):365\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"46","key":"1089_CR42","doi-asserted-by":"crossref","first-page":"29468","DOI":"10.1074\/jbc.271.46.29468","volume":"271","author":"IR Coe","year":"1996","unstructured":"Coe IR, Yao L, Diamond I, Gordon AS. The role of protein kinase C in cellular tolerance to ethanol. J Biol Chem. 1996;271(46):29468\u201372.","journal-title":"J Biol Chem"},{"issue":"5","key":"1089_CR43","first-page":"744","volume":"36","author":"LE Nagy","year":"1989","unstructured":"Nagy LE, Diamond I, Collier K, Lopez L, Ullman B, Gordon AS. Adenosine is required for ethanol-induced heterologous desensitization. Mol Pharmacol. 1989;36(5):744\u20138.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"1089_CR44","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0021-9258(19)39923-5","volume":"265","author":"LE Nagy","year":"1990","unstructured":"Nagy LE, Diamond I, Casso DJ, Franklin C, Gordon AS. Ethanol increases extracellular adenosine by inhibiting adenosine uptake via the nucleoside transporter. J Biol Chem. 1990;265(4):1946\u201351.","journal-title":"J Biol Chem"},{"issue":"2","key":"1089_CR45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11302-013-9391-2","volume":"10","author":"A Ramadan","year":"2014","unstructured":"Ramadan A, Naydenova Z, Stevanovic K, Rose JB, Coe IR. The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity. Purinergic Signal. 2014;10(2):305\u201312.","journal-title":"Purinergic Signal"},{"issue":"8","key":"1089_CR46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11910-018-0859-x","volume":"18","author":"J Rice","year":"2018","unstructured":"Rice J, Cameron M. Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep. 2018;18(8):50.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1089_CR47","unstructured":"Multiple Sclerosis Society UK. Cannabis. 2014. https:\/\/www.mssociety.org.uk\/about-ms\/treatments-and-therapies\/cannabis#:~:text=One%20in%20five%20people%20with,up%20of%20compounds%20called%20cannabinoids. Accessed 20 Apr 2021."},{"issue":"20","key":"1089_CR48","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","volume":"103","author":"EJ Carrier","year":"2006","unstructured":"Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA. 2006;103(20):7895\u2013900.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1089_CR49","unstructured":"Marinol (dronabiol) capsules. Summary of product characteristics. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018651s029lbl.pdf. Accessed 20 Apr 2021."},{"key":"1089_CR50","unstructured":"Syndros (dronabinol) oral solution. Summary of product characteristics. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205525s003lbl.pdf. Accessed 20 Apr 2021."},{"key":"1089_CR51","unstructured":"Sativex product monograph. 2019. https:\/\/omr.bayer.ca\/omr\/online\/sativex-pm-en.pdf. Accessed 20 Apr 2021."},{"key":"1089_CR52","doi-asserted-by":"crossref","unstructured":"Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16(5):276\u201382.","DOI":"10.1093\/jat\/16.5.276"},{"key":"1089_CR53","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O\u2019Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1089_CR54","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/dta.2092","volume":"9","author":"MJ Swortwood","year":"2017","unstructured":"Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Test Anal. 2017;9(6):905\u201315.","journal-title":"Drug Test Anal"},{"key":"1089_CR55","unstructured":"Persantine tablets. US summary of product characteristics. 2019. https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Persantine%20Tabs\/PersTab.pdf. Accessed 20 Apr 2021."},{"key":"1089_CR56","unstructured":"Dilazep hydrochloride tablets 100mg \"SAWAI\". Summary of product characteristics. 2014. Available from: https:\/\/www.rad-ar.or.jp\/siori\/english\/kekka.cgi?n=39136. Accessed 27 Oct 2020."},{"key":"1089_CR57","unstructured":"Haustein K-O. Dipyridamol: sein heutiger Stellenwert. Dtsch Arztebl Int. 1998;95(14):A-817."},{"issue":"1","key":"1089_CR58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1074\/jbc.M105324200","volume":"277","author":"F Visser","year":"2002","unstructured":"Visser F, Vickers MF, Ng AM, Baldwin SA, Young JD, Cass CE. Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem. 2002;277(1):395\u2013401.","journal-title":"J Biol Chem"},{"issue":"10","key":"1089_CR59","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/2472555219870123","volume":"24","author":"S Rehan","year":"2019","unstructured":"Rehan S, Shahid S, Salminen TA, Jaakola VP, Paavilainen VO. Current progress on equilibrative nucleoside transporter function and inhibitor design. SLAS Discov. 2019;24(10):953\u201368.","journal-title":"SLAS Discov"},{"key":"1089_CR60","doi-asserted-by":"publisher","unstructured":"Patil SB, Norman K, Robins S, Crosdale D, Nylander S, Francis S, et al. Inhibition of thrombosis by AZD6140 via selective blockade of the P2Y12 receptor in a murine laser-injury model. J Thromb Haemost. 2007. https:\/\/doi.org\/10.1111\/J.1538-7836.2007.TB03189.X.","DOI":"10.1111\/J.1538-7836.2007.TB03189.X"},{"issue":"10","key":"1089_CR61","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","volume":"11","author":"S Nylander","year":"2013","unstructured":"Nylander S, Femia EA, Scavone M, Berntsson P, Aszt\u00e9ly AK, Nelander K, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost. 2013;11(10):1867\u201376.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1089_CR62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","volume":"19","author":"D Armstrong","year":"2014","unstructured":"Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19(2):209\u201319.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"1089_CR63","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","volume":"17","author":"JJ van Giezen","year":"2012","unstructured":"van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bj\u00f6rkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther. 2012;17(2):164\u201372.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"23","key":"1089_CR64","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jchromb.2011.06.023","volume":"879","author":"H Sill\u00e9n","year":"2011","unstructured":"Sill\u00e9n H, Cook M, Davis P. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS\/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(23):2315\u201322.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"1089_CR65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCINTERVENTIONS.113.000293","volume":"6","author":"D Alexopoulos","year":"2013","unstructured":"Alexopoulos D, Moulias A, Koutsogiannis N, Xanthopoulou I, Kakkavas A, Mavronasiou E, et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv. 2013;6(3):277\u201383.","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"1089_CR66","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacc.2012.11.032","volume":"61","author":"A Wittfeldt","year":"2013","unstructured":"Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61(7):723\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1089_CR67","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","volume":"63","author":"L Bonello","year":"2014","unstructured":"Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63(9):872\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"1089_CR68","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"CP Cannon","year":"2007","unstructured":"Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50(19):1844\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1089_CR69","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"key":"1089_CR70","unstructured":"Pletal 50 mg tablets. Summary of product characteristics. 2016. https:\/\/www.medicines.org.uk\/emc\/product\/164\/smpc#gref. Accessed 20 Apr 2021."},{"key":"1089_CR71","doi-asserted-by":"crossref","unstructured":"Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001;19(4):369\u201386.","DOI":"10.1111\/j.1527-3466.2001.tb00076.x"},{"issue":"2","key":"1089_CR72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10072-014-2007-y","volume":"36","author":"YJ Wang","year":"2015","unstructured":"Wang YJ, Li R, Yan JW, Wan YN, Tao JH, Chen B, et al. The epidemiology of alcohol consumption and multiple sclerosis: a review. Neurol Sci. 2015;36(2):189\u201396.","journal-title":"Neurol Sci"},{"issue":"33","key":"1089_CR73","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1089_CR74","unstructured":"Nimotop 30mg tablets. Summary of product characteristics, 2017. https:\/\/www.medicines.org.uk\/emc\/medicine\/8086\/SPC#gref. Accessed 20 Apr 2021."},{"issue":"1","key":"1089_CR75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0014-2999(93)90517-L","volume":"238","author":"J Deckert","year":"1993","unstructured":"Deckert J, Bereznai B, Hennemann A, Gsell W, G\u00f6tz M, Fritze J, et al. Nimodipine inhibits [3H]nitrobenzylthioinosine binding to the adenosine transporter in human brain. Eur J Pharmacol. 1993;238(1):131\u20133.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1089_CR76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2165\/00003088-199834060-00003","volume":"34","author":"R Kirsten","year":"1998","unstructured":"Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet. 1998;34(6):457\u201382.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1089_CR77","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2002.128127","volume":"72","author":"P Blardi","year":"2002","unstructured":"Blardi P, Urso R, De Lalla A, Volpi L, Perri TD, Auteri A. Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin Pharmacol Ther. 2002;72(5):556\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1089_CR78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/FJC.0b013e31820eb788","volume":"59","author":"RW Li","year":"2012","unstructured":"Li RW, Yang C, Sit AS, Lin SY, Ho EY, Leung GP. Physiological and pharmacological roles of vascular nucleoside transporters. J Cardiovasc Pharmacol. 2012;59(1):10\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1\u20133","key":"1089_CR79","first-page":"15","volume":"612","author":"RW Li","year":"2009","unstructured":"Li RW, Seto SW, Au AL, Kwan YW, Chan SW, Lee SM, et al. Inhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells. Eur J Pharmacol. 2009;612(1\u20133):15\u201320.","journal-title":"Eur J Pharmacol"},{"key":"1089_CR80","doi-asserted-by":"crossref","unstructured":"Meador W, Salter AR, Rinker 2nd JR. Symptomatic management of multiple sclerosis-associated tremor among participants in the NARCOMS Registry. Int J MS Care. 2016;18(3):147\u201353","DOI":"10.7224\/1537-2073.2015-008"},{"issue":"2","key":"1089_CR81","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00000542-200002000-00041","volume":"92","author":"CN Seubert","year":"2000","unstructured":"Seubert CN, Morey TE, Martynyuk AE, Cucchiara RF, Dennis DM. Midazolam selectively potentiates the A(2A) - but not A1-receptor-mediated effects of adenosine: role of nucleoside transport inhibition and clinical implications. Anesthesiology. 2000;92(2):567\u201377.","journal-title":"Anesthesiology"},{"issue":"10","key":"1089_CR82","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","volume":"34","author":"X An","year":"2010","unstructured":"An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255\u201368.","journal-title":"Leuk Res"},{"issue":"36","key":"1089_CR83","doi-asserted-by":"crossref","first-page":"18809","DOI":"10.1074\/jbc.M116.741074","volume":"291","author":"VL Damaraju","year":"2016","unstructured":"Damaraju VL, Weber D, Kuzma M, Cass CE, Sawyer MB. Selective inhibition of human equilibrative and concentrative nucleoside transporters by BCR-ABL kinase inhibitors: identification of key hENT1 amino acid residues for interaction with BCR-ABL kinase inhibitors. J Biol Chem. 2016;291(36):18809\u201317.","journal-title":"J Biol Chem"},{"issue":"1","key":"1089_CR84","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1046\/j.1523-1755.1998.00727.x","volume":"53","author":"R Guieu","year":"1998","unstructured":"Guieu R, Dussol B, Devaux C, Sampol J, Brunet P, Rochat H, et al. Interactions between cyclosporine A and adenosine in kidney transplant recipients. Kidney Int. 1998;53(1):200\u20134.","journal-title":"Kidney Int"},{"issue":"3","key":"1089_CR85","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00547559","volume":"23","author":"A Dresse","year":"1982","unstructured":"Dresse A, Chevolet C, Delapierre D, Masset H, Weisenberger H, Bozler G, et al. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol. 1982;23(3):229\u201334.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1089_CR86","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2013.08.063","volume":"86","author":"C Wang","year":"2013","unstructured":"Wang C, Lin W, Playa H, Sun S, Cameron K, Buolamwini JK. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters: identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol. 2013;86(11):1531\u201340.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"1089_CR87","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2165\/00003088-200342100-00003","volume":"42","author":"T Lenz","year":"2003","unstructured":"Lenz T, Wilson A. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. Clin Pharmacokinet. 2003;42(10):909\u201320.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1089_CR88","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jps.2600780404","volume":"78","author":"MP Sambhi","year":"1989","unstructured":"Sambhi MP, Kannan R, Thananopavarn C, Ookhtens M, Gudenzi M. Therapeutic tolerance, hemodynamic effects, and oral dose kinetics of dilazep dihydrochloride in hypertensive patients. J Pharm Sci. 1989;78(4):281\u20134.","journal-title":"J Pharm Sci"},{"key":"1089_CR89","unstructured":"Brilique 60 mg film-coated tablets. Summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brilique-epar-product-information_en.pdf. Accessed 18 Oct 2021."},{"key":"1089_CR90","unstructured":"Eschenhagen T. Treatment of hypertension. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's: the pharmacological basis of therapeutics, 13th edn. New York: McGraw-Hill Education; 2017."},{"issue":"Suppl. 3","key":"1089_CR91","first-page":"195s","volume":"22","author":"RJ Dow","year":"1986","unstructured":"Dow RJ, Graham DJM. A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride. Br J Clin Pharmacol. 1986;22(Suppl. 3):195s\u2013202s.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl. 7","key":"1089_CR92","first-page":"S982","volume":"6","author":"W Kirch","year":"1984","unstructured":"Kirch W, Hutt HJ, Heidemann H, R\u00e4msch K, Janisch HD, Ohnhaus EE. Drug interactions with nitrendipine. J Cardiovasc Pharmacol. 1984;6(Suppl. 7):S982\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl. 7","key":"1089_CR93","first-page":"S977","volume":"6","author":"KC Lasseter","year":"1984","unstructured":"Lasseter KC, Shamblen EC, Murdoch AA, Burkholder DE, Krol GJ, Taylor RJ Jr, et al. Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. J Cardiovasc Pharmacol. 1984;6(Suppl. 7):S977\u201381.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl. 7","key":"1089_CR94","first-page":"S968","volume":"6","author":"J Kann","year":"1984","unstructured":"Kann J, Krol GJ, Raemsch KD, Burkholder DE, Levitt MJ. Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. J Cardiovasc Pharmacol Ther. 1984;6(Suppl. 7):S968\u201373.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1089_CR95","doi-asserted-by":"crossref","unstructured":"Goa KL, Sorkin EM. Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs. 1987;33(2):123\u201355.","DOI":"10.2165\/00003495-198733020-00003"},{"issue":"5","key":"1089_CR96","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clpt.2006.08.003","volume":"80","author":"JA Perini","year":"2006","unstructured":"Perini JA, Suarez-Kurtz G. Impact of CYP2C9*3\/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther. 2006;80(5):549\u201351.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1089_CR97","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2008.03201.x","volume":"66","author":"B Link","year":"2008","unstructured":"Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, et al. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol. 2008;66(4):473\u201384.","journal-title":"Br J Clin Pharmacol"},{"key":"1089_CR98","unstructured":"Midazolam 5mg\/ml, solution for injection\/infusion. Summary of product characteristics. 2020. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/6420\/smpc#gref. Accessed 18 Oct 2021."},{"issue":"12","key":"1089_CR99","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","volume":"58","author":"X Tian","year":"2018","unstructured":"Tian X, Zhang H, Heimbach T, He H, Buchbinder A, Aghoghovbia M, et al. Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor. J Clin Pharmacol. 2018;58(12):1533\u201340.","journal-title":"J Clin Pharmacol"},{"key":"1089_CR100","unstructured":"Iclusig\u00ae 15\/30\/45 mg film-coated tablets. Summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/iclusig-epar-product-information_en.pdf. Accessed 18 Oct 2021."},{"key":"1089_CR101","unstructured":"Bosulif\u00ae 100\/400\/500 mg film-coated tablets. Summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bosulif-epar-product-information_en.pdf. Accessed 18 Oct 2021."},{"issue":"7","key":"1089_CR102","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.107.018267","volume":"36","author":"LJ Christopher","year":"2008","unstructured":"Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metabol Dispos. 2008;36(7):1357\u201364.","journal-title":"Drug Metabol Dispos."},{"key":"1089_CR103","unstructured":"Sprycel\u00ae 20\/50\/70\/ 80\/100\/140 mg film-coated tablets. Summary of product characteristics. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sprycel-epar-product-information_en.pdf. Accessed 18 Oct 2021."},{"key":"1089_CR104","unstructured":"Glivec\u00ae 100 mg hard capsules. Summary of product characteristics. 2006. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/glivec-epar-product-information_en.pdf. Accessed 18 Oct 2021."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01089-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T01:19:14Z","timestamp":1643937554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01089-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,11]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01089-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,11]]},"assertion":[{"value":"7 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RH served as an external clinical pharmacology expert advisor for various aspects in the clinical development of cladribine, and received financial support for research, consulting, and training services from Merck Healthcare KGaA, Darmstadt, Germany. PK served as an external pharmacology expert advisor for in vitro transporter studies. He is a co-founder of Habilitas Kft, which received financial support for generation of an Internal Transporter Report from Merck Healthcare KGaA Darmstadt, Germany. He was also an employee of Solvo Biotechnology, Budapest, Hungary, outside this advisory work. ASK, MF, and AB are employees of Merck Healthcare KGaA Darmstadt, Germany. AG was an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA at the time of the study, and is currently a consultant to Merck Healthcare KGaA, Darmstadt, Germany. AM was at the time of preparation of this manuscript, an employee of the Merck Institute of Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to Merck KGaA\u2019s Data Sharing Policy. All requests should be submitted in writing to Merck KGaA\u2019s data sharing portal: . When Merck KGaA has a co-research, co-development, or co-marketing or co-promotion agreement, or when the product has been out-licensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, Merck KGaA will endeavor to gain agreement to share data in response to requests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}